Morphic Holding, Inc is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its preclinical pipeline, including its lead wholly-owned program for alpha 4 and beta 7-specific integrin inhibitors affecting inflammation into clinical development for the treatment of inflammatory bowel disease (IBD). It is also developing MORF-720, a selective oral specific integrin inhibitor into clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).